Abstract：Objective To investigate the effect of Recombinant Human Thrombopoietin in the treatment of acute leukemia with thrombocytopenia after chemotherapy.Methods A total of 60 acute leukemia patients with thrombocytopenia after chemotherapy in the Department of Hematologic Lymphoma of the First People′s Hospital of Foshan City from January 2019 to January 2021 were selected as the study subjects,and they were divided into observation group(30 cases) and control group (30 cases) by computer two-color ball grouping method.The patients in the observation group were treated with Recombinant Human Thrombopoietin,and the patients in the control group were treated with Recombinant Human Interleukin-11.The platelet improvement time,platelet levels before and after treatment and adverse drug reactions were compared between the two groups.Results The times of duration of of platelet index below 50×109/L and platelet index recovery to 70×109/L in the observation group were shorter than those in the control group,and the differences were statistically significant (P<0.05).The level of platelet in the two groups after treatment were higher than those before treatment,the differences were statistically significant (P<0.05).The level of platelet in observation group was higher than that in the control group after treatment,the difference was statistically significant (P<0.05).The total incidence of adverse drug reactions in observation group was lower than that in control group,the difference was statistically significant (P<0.05).Conclusion Recombinant Human Thrombopoietin is effective and safe in the treatment of acute leukemia with thrombocytopenia after chemotherapy.
戚永磊；赵莹. 重组人促血小板生成素治疗急性白血病化疗后血小板减少症的效果[J]. 中国当代医药, 2022, 29(14): 90-92.
QI Yonglei；ZHAO Ying. Effect of Recombinant Human Thrombocytopenia in the treatment of acute leukemia with thrombocytopenia after chemotherapy. 中国当代医药, 2022, 29(14): 90-92.
京公网安备 11010502046607号